基本信息 产品详情 公司简介 推荐产品
  • 首页
  • 个人中心
  • 委托采购
  • 采购清单
网站主页 DLL3抗体 DLL3抗体
  • DLL3抗体—艾普蒂
  • DLL3抗体—艾普蒂
  • DLL3抗体—艾普蒂

1/3

DLL3抗体—艾普蒂

Mouse Monoclonal DLL3 Antibody
询价 20μl 起订
50μl 起订
100μl 起订
上海 更新日期：2025-05-16

上海切尔齐生物科技有限公司

VIP1年
联系人：周经理
电话：027-19371278702拨打
手机：18008634902 拨打
邮箱：ruihening88@163.com

产品详情:

中文名称：
DLL3抗体
英文名称：
Mouse Monoclonal DLL3 Antibody
品牌：
艾普蒂
产地：
武汉
保存条件：
Stored at -20°C for 1476 year. Avoid repeated freeze / thaw cycles.
产品类别：
抗体
重组：
否
应用：
WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性：
Human,Mouse,Rat
宿主：
Mouse
偶联物：
无
靶点：
DLL3

验证与应用

应用及物种
WB1/500 - 1/2000 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC1/200 - 1/1000 Human,Mouse,Rat
ICC1/200 - 1/1000 Human,Mouse,Rat
FCM1/200 - 1/400 Human,Mouse,Rat
Elisa1/10000 Human,Mouse,Rat
   

产品详情

AliasesSCDO1
Entrez GeneID10683
clone6H4C4
WB Predicted band size65KDa
Host/IsotypeMouse IgG2a
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman, Rat
ImmunogenPurified recombinant fragment of human DLL3 (AA: EXTRA(27-226)) expressed in E. Coli.
FormulationPurified antibody in PBS with 0.05% sodium azide

+ +

  •  

     

       Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    


  •  

     

       Western blot analysis using DLL3 mouse mAb against Hela (1)cell lysate.    


  •  

     

       Immunofluorescence analysis of Hela cells using DLL3 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    


  •  

     

       Flow cytometric analysis of C6 cells using DLL3 mouse mAb (green) and negative control (red).    


  •  

     

       Immunohistochemical analysis of paraffin-embedded human cervical carcinoma tissues using DLL3 mouse mAb with DAB staining.    


  •  

     

       Immunohistochemical analysis of paraffin-embedded human rectal cancer tissues using DLL3 mouse mAb with DAB staining.    


           

参考文献

以下是关于DLL3抗体的3篇代表性文献的简要信息：

1. **文献名称**：*DLL3: An Emerging Target in Small Cell Lung Cancer*

**作者**：Saunders LR, et al.

**摘要**：该研究探讨了DLL3在小细胞肺癌(SCLC)中的高表达及其作为治疗靶点的潜力，并介绍了靶向DLL3的抗体药物偶联物(ADC)Rovalpituzumab Tesirine(Rova-T)的临床前数据，显示其在肿瘤模型中的显著抗肿瘤活性。

2. **文献名称**：*Rovalpituzumab Tesirine, a DLL3-Targeted Antibody-Drug Conjugate, in Recurrent Small-Cell Lung Cancer: A First-in-Human, First-in-Class, Open-Label, Phase 1 Study*

**作者**：Rudin CM, et al.

**摘要**：这项I期临床试验评估了Rova-T在复发SCLC患者中的安全性和初步疗效，结果显示部分患者达到客观缓解，验证了DLL3作为治疗靶点的可行性，但也提示需关注后续耐药性和毒性问题。

3. **文献名称**：*DLL3 as a Therapeutic Target in High-Grade Neuroendocrine Tumors*

**作者**：Puca L, et al.

**摘要**：研究分析了DLL3在高级别神经内分泌肿瘤中的表达特征，并开发了一种新型双特异性抗体，可同时靶向DLL3和CD3.通过激活T细胞实现肿瘤特异性杀伤，为免疫疗法提供了新思路。

4. **文献名称**：*Structural Basis of Notch Recognition by Human DLL3*

**作者**：Ladi E, et al.

**摘要**：通过解析DLL3蛋白的晶体结构，揭示了其与Notch受体相互作用的分子机制，为设计高特异性DLL3抗体及优化靶向药物的结合能力提供了结构生物学依据。

这些文献涵盖了DLL3抗体的基础机制、药物开发及临床转化研究，反映了其在肿瘤治疗中的研究进展与挑战。

       

背景信息

**Background of DLL3 Antibodies**

DLL3 (Delta-like protein 3) is a ligand in the Notch signaling pathway, primarily involved in cell differentiation and development. Unlike other Delta-like family members, DLL3 is atypically localized in the Golgi apparatus and exhibits limited surface expression in normal tissues. However, DLL3 is frequently overexpressed in neuroendocrine tumors, such as small cell lung cancer (SCLC), large cell neuroendocrine carcinoma, and neuroendocrine prostate cancer, making it a promising therapeutic target.

DLL3-targeted antibodies, particularly antibody-drug conjugates (ADCs) and bispecific antibodies, have emerged as potential therapies. Rovalpituzumab tesirine (Rova-T), an ADC linking an anti-DLL3 antibody to a cytotoxic payload, showed early promise in SCLC but faced setbacks in clinical trials due to limited efficacy and toxicity. Despite this, research continues to explore improved DLL3-targeting strategies, including bispecific antibodies engaging T cells (e.g., DLL3-CD3 bispecifics) and combination therapies with immune checkpoint inhibitors.

Challenges include understanding DLL3's role in Notch pathway regulation, addressing tumor heterogeneity, and mitigating resistance mechanisms linked to Notch activation. Ongoing studies aim to refine targeting approaches, enhance therapeutic windows, and identify predictive biomarkers to optimize patient selection. DLL3 remains a compelling focus in precision oncology for neuroendocrine malignancies.

       
DLL3抗体;DLL3;DLL3 Antibody;

公司简介

是一家科研、开发、生产和销售为一体的科技型企业，

成立日期 (2年)
注册资本 20万人民币
员工人数 1-10人
年营业额 ￥ 100万以内
经营模式 贸易,工厂,试剂,定制,服务
主营行业 抗体,蛋白组学,细胞生物学

DLL3抗体相关厂家报价

内容声明
official 进入官方账号
拨打电话 立即询价